包涵体蛋白复性的几种方法

外源基因在大肠杆菌中高水平表达时,通常会形成无活性的蛋白聚集体即包涵体。包涵体富含表达的重组蛋白,经分离、变性溶解后须再经过一个合适的复性过程实现变性蛋白的重折叠,才能够得到生物活性蛋白。     

内生真菌Shiraiasp.Slf 14中菊粉酶基因的克隆、表达及包涵体复性

为了实现内生真菌Shiraia sp.Slf 14菊粉酶基因在大肠杆菌中的高效表达,建立有效的包涵体复性技术,获得有活性的重组菊粉酶,本研究通过提取Shiraia sp.Slf 14的总RNA,反转录合成cDNA,设计PCR引物扩增出菊粉酶基因,将其克隆至pET-22b(+)载体后转入E.coli BL21(DE3),利用SDS-PAGE法检测IPTG诱导表达后重组蛋白的表达情况,并进一步检测了包涵体复性及重组酶酶活情况,最终成功获得了相对分子量为62.07 kD的重组蛋白,成功复性包涵体,复性率为25.23%,重组菊粉酶活力为6.84 U/m L。本研究为活性重组菊粉酶的获得及包涵体复性提供了新的方法和依据。     

蛋白质的排阻色谱复性的新进展

外源蛋白在大肠杆菌中高效表达时 ,常常形成不溶的、无活性的包涵体 ,包涵体蛋白的复性是重组蛋白生产过程中的一个技术难题。排阻色谱 (sizeexclusionchromatography ,SEC)用于蛋白复性是一种较新的、适用于任何一种蛋白的方法 ,与常用的稀释复性法相比 ,它能在高的起始蛋白浓度下对蛋白进行复性 ,活性回收率较高 ,同时又能使目标蛋白得到一定程度的纯化。对使用SEC复性的进展进行了评述 ,其内容包括SEC复性的原理及其复性过程中的影响因素 ,并对其未来发展进行了展望。     

蛇毒金属蛋白酶Alfimeprase在大肠杆菌中的表达、纯化及活性检测

目的:应用大肠杆菌表达系统表达纤溶性蛇毒金属蛋白酶Alfimeprase。方法:运用PCR技术扩增人工合成的目的基因,引入Nde Ⅰ、EcoR Ⅰ双酶切位点;目的基因经Nde Ⅰ、EcoR Ⅰ双酶切后,克隆到pET22b载体上,然后将重组质粒转化大肠杆菌BL21(DE3)进行胞内表达,对获得的包涵体进行体外透析复性;应用纤维蛋白原水解法、纤维蛋白平板法和纤维蛋白层叠法检测复性后蛋白的降纤活性。结果:目的蛋白以包涵体形式在大肠杆菌中获得高表达,复性后的蛋白具有降解纤维蛋白(原)的活性。结论:Alfimeprase包涵体可以通过复性获得活性产物。     

原核基因工程中的包涵体

包涵体是原核基因工程的特有产物,其中表达的蛋白产物是以无活性、不溶解的形式存在。包涵体特性、蛋白回收及活性恢复是生物工程研究的重要课题。文章对包涵体特性、回收及产物提取,重组蛋白的复性及纯化作了综述。     

包涵体蛋白的分离和色谱法体外复性纯化研究进展

重组蛋白在大肠杆菌中表达多为无活性的包涵体形式,须经洗涤、溶解、复性后才能得到生物活性蛋白。综述了近年来包涵体蛋白分离纯化和复性技术研究进展,重点讨论了色谱法复性技术的应用,包括尺寸排阻色谱、亲和色谱、离子交换色谱、疏水相互作用色谱、固定化脂质体色谱、扩张床吸附色谱的进展情况。     

人血小板衍生生长因子BB亚型包涵体复性与纯化

目的:优化人血小板衍生生长因子BB亚型(PGDF-BB)包涵体复性方法与纯化条件,获得具有较好生物活性的重组PGDF-BB蛋白。方法:对PGDF-BB包涵体以梯度尿素进行变性,选择最佳包涵体变性浓度;比较不同复性条件下的复性率,稳定PGDF-BB包涵体复性方法;参照该蛋白的理化性质,选择适合PGDF-BB重组蛋白的纯化方法。结果:原核系统内实现了PGDF-BB的高表达;通过优化包涵体复性方法,重组蛋白的包涵体复性率可达40%以上;经过多个纯化方法相结合,PGDF-BB的纯度达到95%。结论:通过实验条件的优化,提高了PGDF-BB包涵体复性率,获得高纯度、高生物活性的重组PGDF-BB蛋白。     

重组蛋白ApSerpin-FA72的包涵体复性及活性研究

[目的]原核表达及制备重组光滑鳖甲丝氨酸蛋白酶抑制剂(Ap Serpin-FA72),探索包涵体最优复性条件与最适酶反应条件。[方法]采用超声破碎获得大量包涵体,通过包涵体的洗涤、包涵体的溶解方法对包涵体进行纯化,获得高纯度的包涵体进行复性液成分与复性方法的摸索。测定Trx A-Ap Serpin-FA72对胰蛋白酶的IC50、最适反应p H和最适反应温度。[结果]在32℃、180 r/min、0. 4 mmol/L IPTG浓度下以沉淀形式表达大量蛋白,通过包涵体复性在含有L-精氨酸复性液中获得有生物活性的Trx A-Ap Serpin-FA72,对胰蛋白酶的IC50为0. 48μmol/L,p H在7～9,温度在60℃时有较高的抑制活性。[结论]L-精氨酸是复性液中重要的组成部分,复性的重组蛋白Trx A-Ap SerpinFA72对胰蛋白酶有较强的抑制能力,是一种热稳定较好的弱碱性胰蛋白酶抑制剂。     

解淀粉芽孢杆菌α-淀粉酶基因的克隆与表达

[目的]实现解淀粉芽孢杆菌α-淀粉酶在大肠杆菌中的高效表达,建立有效的透析复性方法,获得有活性的重组淀粉酶。[方法]以解淀粉芽孢杆菌DSM 7基因组DNA为模板,PCR扩增获得无信号肽的α-淀粉酶结构基因,克隆至p ET-22b(+),转化E.coli BL21(DE3),IPTG诱导表达,SDS-PAGE检测重组蛋白表达情况,采用透析法进行包涵体复性并检测酶活。[结果]成功表达重组蛋白,相对分子量约为54.8k Da,成功复性包涵体,复性效率为22.78%,重组α-淀粉酶酶活力为102.4 U/m L。[结论]实现了解淀粉芽孢杆菌α-淀粉酶在大肠杆菌中的高效表达,包涵体经透析法成功复性,获得具有催化活性的重组淀粉酶。     

破骨细胞形成抑制因子TNFR结构区在大肠杆菌中表达、抗体制备及活性测定

破骨细胞形成抑制因子(OPG)对骨的重建与再吸收有重要调节作用,其TNFR结构区行使抑制破骨细胞形成与活性的功能。通过PCR将该区基因片段克隆出来,插入表达载体PET-28a质粒多克隆位点,重组质粒转入大肠杆菌BL21中进行表达,表达产物以包涵体形式存在,包涵体经变性复性后,亲合层析获得重组蛋白。纯化的产物作为抗原免疫兔,得到较高特异性的兔源多克隆抗体。利用小鼠降血钙实验检测变性复性后产物的活性,结果表明该重组蛋白有一定的生物活性。     

包涵体复性研究进展(英文)

用基因工程技术在大肠杆菌高水平表达重组蛋白时,通常形成无生物活性的包涵体。包涵体在体外经分离、溶解与重折叠后可实现复性,表现为具有生物活性的蛋白。总结了包涵体的相关复性技术,重点介绍重折叠的最新进展情况 。     

Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies

Overexpression of cloned or synthetic genes in Escherichia coli often results in the formation of insoluble protein inclusion bodies. Within the last decade, specific methods and strategies have been developed for preparing active recombinant proteins from these inclusion bodies. Usually, the inclusion bodies can be separated easily from other cell components by centrifugation, solubilized by denaturants such as guanidine hydrochloride (Gdn-HCl) or urea, and then renatured through a refolding process such as dilution or dialysis. Recent improvements in renaturation procedures have included the inhibition of aggregation during refolding by application of low molecular weight additives and matrix-bound renaturation. These methods have made it possible to obtain high yields of biologically active proteins by taking into account process parameters such as protein concentration, redox conditions, temperature, pH, and ionic strength.     

A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.

Many proteins produced in Escherichia coli accumulate in inclusion bodies. We have systematically evaluated the parameters that affect the refolding and renaturation of enzymatically active molecules from bacterial inclusion bodies containing a recombinant single-chain immunotoxin, B3(Fv)-PE38KDEL. This recombinant molecule is composed of the variable domains of monoclonal antibody B3 (B3(Fv)) fused to a truncated mutant form of Pseudomonas exotoxin A (PE38KDEL). This immunotoxin kills carcinoma cells in vitro, causes tumor regression in animal tumor models, and is being developed as an anti-cancer therapeutic agent (Brinkmann et al., 1991, Proc. Natl. Acad. Sci. USA 88, 8616-8620). Like many other recombinant proteins, B3(Fv)-PE38KDEL is produced in E. coli in inclusion bodies and must be denatured and refolded to become active. This requires correct folding, formation of native disulfide bonds, and the association of different domains. All these steps are strongly dependent on the renaturation conditions used. Optimum conditions of refolding were obtained by the addition of reduced and oxidized thiol reagents to promote disulfide bond formation and the addition of a labilizing agent such as L-arginine. Furthermore, the necessity to reactivate proteins at low protein concentrations due to its tendency to aggregate at high concentrations was overcome by a step-by-step addition of denatured and reduced protein into the refolding solution. This approach should be useful for the production of active forms of other recombinant proteins.     

蛋白质复性研究进展

许多蛋白在大肠杆菌中高效表达时,其产物常以无活性的包含体形式存在,包含体蛋白的复性往往是制备这些蛋白的关键步骤之一,蛋白复性包括肽链折叠和分子内二硫键的氧化这两个互相影响的过程,本文综述了蛋白折叠过程的研究进展,及促进蛋白折叠和二硫键氧化的方法。     

Oxidative renaturation of lysozyme at high concentrations

Newly synthesized cloned gene proteins expressed in bacteria frequently accumulate in insoluble aggregates or inclusion bodies. Active protein can be recovered by solubilization of inclusion bodies followed by renaturation of the solubilized (unfolded) protein. The recovery of active protein is highly dependent on the renaturation conditions chosen. The renaturation process is generally conducted at low protein concentrations (0.01-0.2 mg/mL) to avoid aggregation. We have investigated the potential of successfully refolding reduced and denatured hen egg white lysozyme at high concentrations (1 and 5 mg/mL). By varying the composition of the renaturation media, optimum conditions which kinetically favor proper folding over inactivation were found. Solubilizing agents such as guanidinium chloride (GdmCl) and folding aids such as L-arginine present in low concentrations during refolding effectively enhanced renaturation yields by suppressing aggregation resulting in reactivation yields as high as 95%. Quantitatively the kinetic competition between lysozyme folding and aggregation can be described using first-order kinetics for the renaturation reaction and third-order kinetics for the overall aggregation pathway. The rate constants for both reactions have been found to be strongly dependent on denaturant and thiol concentration. This strategy supercedes the necessity to reactivate proteins at low concentrations using large renaturation volumes. The marked increase in volumetric productivity makes this a viable option for recovering biologically active protein efficiently and in high yield in vitro from proteins produced as inclusion bodies within microbial cells. (c) 1997 John Wiley & Sons, Inc. Biotechnol Bioeng 54: 221-230, 1997.     

液胶色谱柱复性在低分子量尿激酶原突变体（DscuPA—32K）中的应用

将构建一种具溶栓和抗栓以重功能尿激酶原突变体（DscuPA-32K)基因,在大肠杆菌中进行表达。由于DscuPA-32K分子较大并且表达量较高,目的的性质基本以包涵体的形式存在。包涵体中的蛋白质是无活性的蛋白质,为了获得有活性的蛋白质,就需要对包涵体进行变性及复性。尝试了一种新的凝胶色谱柱复性方法,并通过柱复性方法与常规的稀释复性方法进行了比较,发现柱复性方法明显优于稀释复性方法,具有成本低,效率高,并对目的的蛋白质（DscuPA-32K)进行了初步纯化等优点,尤其对酶这一类容易失活降解的蛋白质进行复性时,很值得进行推广应用。     

Renaturation, purification and characterization of streptokinase expressed as inclusion body in recombinant E. coli

Recombinant protein purification is facilitated using high expression systems which produce larger quantities of streptokinase protein as inclusion bodies. As the accumulation of active streptokinase is toxic to the host cells, we have optimized the conditions to achieve large amounts of streptokinase in the form of inclusion bodies. The solubility and yield of pure protein are highly dependent on various combinations of chemical additives, ionic and non-ionic detergents and salts, with solubilizing agents followed by refolding of denatured protein into active form. As the extraction of the purified streptokinase from inclusion bodies requires denaturation and a subsequent refolding step, careful balancing steps were needed to develop under different controlled conditions. Here the purified fragments of refolded proteins were screened to select the conditions that yield the active streptokinase having native conformation. The maximum specific activity of the purified streptokinase was achieved by these methods. The refolded recombinant streptokinase was analyzed by RP-HPLC showing a purity of 99%. Size exclusion chromatography profile shows that there are minimal aggregates in the active streptokinase protein and the percentage of renaturation is around 99%.     

Effect of chemical chaperones in improving the solubility of recombinant proteins in Escherichia coli

The recovery of active proteins from inclusion bodies usually involves chaotrope-induced denaturation, followed by refolding of the unfolded protein. The efficiency of renaturation is low, leading to reduced yield of the final product. In this work, we report that recombinant proteins can be overexpressed in the soluble form in the host expression system by incorporating compatible solutes during protein expression. Green fluorescent protein (GFP), which was otherwise expressed as inclusion bodies, could be made to partition off into the soluble fraction when sorbitol and arginine, but not ethylene glycol, were present in the growth medium. Arginine and sorbitol increased the production of soluble protein, while ethylene glycol did not. Production of ATP increased in the presence of sorbitol and arginine, but not ethylene glycol. A control experiment with fructose addition indicated that protein solubilization was not due to a simple ATP increase. We have successfully reproduced these results with the N-terminal domain of HypF (HypF-N), a bacterial protein which forms inclusion bodies in Escherichia coli. Instead of forming inclusion bodies, HypF-N could be expressed as a soluble protein in the presence of sorbitol, arginine, and trehalose in the expression medium.     

Highly efficient production of soluble proteins from insoluble inclusion bodies by a two-step-denaturing and refolding method

The production of recombinant proteins in a large scale is important for protein functional and structural studies, particularly by using Escherichia coli over-expression systems; however, approximate 70% of recombinant proteins are over-expressed as insoluble inclusion bodies. Here we presented an efficient method for generating soluble proteins from inclusion bodies by using two steps of denaturation and one step of refolding. We first demonstrated the advantages of this method over a conventional procedure with one denaturation step and one refolding step using three proteins with different folding properties. The refolded proteins were found to be active using in vitro tests and a bioassay. We then tested the general applicability of this method by analyzing 88 proteins from human and other organisms, all of which were expressed as inclusion bodies. We found that about 76% of these proteins were refolded with an average of >75% yield of soluble proteins. This "two-step-denaturing and refolding" (2DR) method is simple, highly efficient and generally applicable; it can be utilized to obtain active recombinant proteins for both basic research and industrial purposes.     

L-cysteine-enhanced renaturation of bioactive soluble tumor necrosis factor ligand family member LIGHT from inclusion bodies in Escherichia coli

LIGHT is a membrane-bound protein that belongs to the tumor necrosis factor (TNF) superfamily ligands. In this study, we established an effective strategy for producing a bioactive soluble form of LIGHT (sLIGHT), an extracellular region (Ile??-Val2??) of human LIGHT. Because sLIGHT was expressed as inclusion bodies in Escherichia coli, we investigated reagents that enhance the renaturation of sLIGHT from the inclusion bodies. Interestingly, L-cysteine in the denaturation buffer containing 3.5 M guanidine hydrochloride significantly improved the renaturation efficiency of sLIGHT. The effect of L-cysteine was synergistically enhanced by L-arginine in the refolding buffer. The optimal concentrations of L-cysteine and L-arginine in the denaturation and refolding buffers were 8 mM and 0.8 M, respectively. With these buffers, approximately 90 mg of sLIGHT was purified from 200 g of frozen E. coli cells. sLIGHT thus obtained significantly induced apoptosis in the WiDr human colon adenocarcinoma cell line at nanomolar concentrations, the same amount of sLIGHT that was produced by Sf9 insect cells. These results suggest that L-cysteine in the denaturation buffer enhances the renaturation of recombinant proteins from inclusion bodies in E. coli.